Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sucrosomial Iron vs Oral Iron Sulfate in UC Patients with IDA
NCT05225545Phase 3Recruiting
- Sponsor
- American University of Beirut Medical Center
- Start
- Nov 2019
- Primary completion
- May 2024
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised trial of sucrosomial iron in iron deficiency anemia (IDA) (2 arms), sponsored by American University of Beirut Medical Center. Primary endpoint: Tolerability of experimental product at 12 weeks. Started Nov 2019; status: recruiting.
02
Drugs
sucrosomial iron
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05225545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225545.